{
    "nctId": "NCT00193037",
    "briefTitle": "Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer",
    "officialTitle": "A Phase II Randomized Crossover Study Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 102,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\nTo be included in this study, you must meet the following criteria:\n\n* Metastatic breast cancer confirmed by biopsy\n* Prior adjuvant/neoadjuvant treatment allowed\n* Measurable disease\n* Able to perform activities of daily living with minimal assistance\n* Age 18 years or older\n* Adequate bone marrow, liver and kidney function\n* Normal heart function\n* Written informed consent\n\nExclusion Criteria:\n\nYou cannot participate in this study if any of the following apply to you:\n\n* Pre-existing moderate peripheral neuropathy\n* History of significant heart disease\n* Meningeal metastases.\n* Prior chemotherapy for metastatic breast cancer\n* No measurable disease (including bone only, pleural effusions, etc.)\n* Receiving Herceptin therapy.\n* Women who are pregnant or lactating.\n\nPlease note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}